Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: NADSYN1

Gene summary for NADSYN1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

NADSYN1

Gene ID

55191

Gene nameNAD synthetase 1
Gene AliasVCRL3
Cytomap11q13.4
Gene Typeprotein-coding
GO ID

GO:0006139

UniProtAcc

Q6IA69


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
55191NADSYN1LZE2THumanEsophagusESCC6.54e-034.15e-010.082
55191NADSYN1LZE4THumanEsophagusESCC2.96e-258.24e-010.0811
55191NADSYN1LZE7THumanEsophagusESCC1.98e-042.50e-010.0667
55191NADSYN1LZE8THumanEsophagusESCC3.30e-561.46e+000.067
55191NADSYN1LZE20THumanEsophagusESCC3.06e-124.49e-010.0662
55191NADSYN1LZE21D1HumanEsophagusHGIN2.30e-033.12e-010.0632
55191NADSYN1LZE22D1HumanEsophagusHGIN1.26e-145.98e-010.0595
55191NADSYN1LZE22THumanEsophagusESCC1.13e-221.23e+000.068
55191NADSYN1LZE24THumanEsophagusESCC2.22e-347.15e-010.0596
55191NADSYN1LZE22D3HumanEsophagusHGIN1.17e-026.66e-010.0653
55191NADSYN1LZE21THumanEsophagusESCC2.87e-075.89e-010.0655
55191NADSYN1P1T-EHumanEsophagusESCC1.76e-177.25e-010.0875
55191NADSYN1P2T-EHumanEsophagusESCC1.71e-961.72e+000.1177
55191NADSYN1P4T-EHumanEsophagusESCC2.05e-407.44e-010.1323
55191NADSYN1P5T-EHumanEsophagusESCC1.50e-141.84e-010.1327
55191NADSYN1P8T-EHumanEsophagusESCC2.66e-1092.18e+000.0889
55191NADSYN1P9T-EHumanEsophagusESCC3.07e-174.02e-010.1131
55191NADSYN1P10T-EHumanEsophagusESCC1.68e-162.64e-010.116
55191NADSYN1P11T-EHumanEsophagusESCC8.43e-165.80e-010.1426
55191NADSYN1P12T-EHumanEsophagusESCC5.27e-163.94e-010.1122
Page: 1 2 3 4 5 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000911720EsophagusHGINnucleotide metabolic process92/2587489/187231.11e-031.36e-0292
GO:00091659EsophagusHGINnucleotide biosynthetic process53/2587254/187231.24e-031.49e-0253
GO:000675320EsophagusHGINnucleoside phosphate metabolic process93/2587497/187231.25e-031.49e-0293
GO:19012939EsophagusHGINnucleoside phosphate biosynthetic process53/2587256/187231.49e-031.73e-0253
GO:0006753110EsophagusESCCnucleoside phosphate metabolic process288/8552497/187231.80e-083.50e-07288
GO:0009117111EsophagusESCCnucleotide metabolic process282/8552489/187234.70e-088.50e-07282
GO:000916516EsophagusESCCnucleotide biosynthetic process150/8552254/187231.12e-051.06e-04150
GO:190129316EsophagusESCCnucleoside phosphate biosynthetic process151/8552256/187231.15e-051.08e-04151
GO:000911722LiverHCCnucleotide metabolic process300/7958489/187231.61e-171.71e-15300
GO:000675322LiverHCCnucleoside phosphate metabolic process304/7958497/187231.78e-171.85e-15304
GO:000916512LiverHCCnucleotide biosynthetic process150/7958254/187236.79e-081.40e-06150
GO:190129312LiverHCCnucleoside phosphate biosynthetic process151/7958256/187236.84e-081.41e-06151
GO:0072525LiverHCCpyridine-containing compound biosynthetic process22/795832/187232.43e-031.18e-0222
GO:0072524LiverHCCpyridine-containing compound metabolic process25/795838/187233.18e-031.47e-0225
GO:0019359LiverHCCnicotinamide nucleotide biosynthetic process19/795829/187231.05e-023.89e-0219
GO:0019363LiverHCCpyridine nucleotide biosynthetic process19/795829/187231.05e-023.89e-0219
GO:000675318Oral cavityOSCCnucleoside phosphate metabolic process247/7305497/187236.28e-078.96e-06247
GO:000911719Oral cavityOSCCnucleotide metabolic process243/7305489/187237.80e-071.09e-05243
GO:19012938Oral cavityOSCCnucleoside phosphate biosynthetic process125/7305256/187238.32e-044.41e-03125
GO:00091658Oral cavityOSCCnucleotide biosynthetic process124/7305254/187238.79e-044.63e-03124
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa012405EsophagusESCCBiosynthesis of cofactors97/4205153/84653.88e-041.35e-036.94e-0497
hsa0124012EsophagusESCCBiosynthesis of cofactors97/4205153/84653.88e-041.35e-036.94e-0497
hsa012402LiverHCCBiosynthesis of cofactors103/4020153/84654.67e-075.05e-062.81e-06103
hsa012403LiverHCCBiosynthesis of cofactors103/4020153/84654.67e-075.05e-062.81e-06103
hsa012404Oral cavityOSCCBiosynthesis of cofactors88/3704153/84653.84e-041.20e-036.12e-0488
hsa0124011Oral cavityOSCCBiosynthesis of cofactors88/3704153/84653.84e-041.20e-036.12e-0488
hsa0124021Oral cavityLPBiosynthesis of cofactors57/2418153/84651.17e-023.91e-022.52e-0257
hsa0124031Oral cavityLPBiosynthesis of cofactors57/2418153/84651.17e-023.91e-022.52e-0257
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
NADSYN1SNVMissense_Mutationnovelc.214G>Tp.Ala72Serp.A72SQ6IA69protein_codingtolerated(0.24)benign(0.009)TCGA-A8-A082-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapy5-fluorouracilCR
NADSYN1SNVMissense_Mutationc.820G>Cp.Asp274Hisp.D274HQ6IA69protein_codingdeleterious(0.01)probably_damaging(0.992)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
NADSYN1SNVMissense_Mutationrs766142745c.1472T>Gp.Val491Glyp.V491GQ6IA69protein_codingdeleterious(0.01)benign(0.25)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
NADSYN1SNVMissense_Mutationnovelc.62G>Ap.Gly21Aspp.G21DQ6IA69protein_codingdeleterious(0)probably_damaging(1)TCGA-BH-A0GZ-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapyarimidexSD
NADSYN1SNVMissense_Mutationrs766142745c.1472N>Gp.Val491Glyp.V491GQ6IA69protein_codingdeleterious(0.01)benign(0.25)TCGA-D8-A1X9-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapyadriamycin+cyclophosphamideSD
NADSYN1SNVMissense_Mutationc.1789N>Ap.Glu597Lysp.E597KQ6IA69protein_codingdeleterious(0)probably_damaging(0.984)TCGA-D8-A27G-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
NADSYN1SNVMissense_Mutationrs766142745c.1472T>Gp.Val491Glyp.V491GQ6IA69protein_codingdeleterious(0.01)benign(0.25)TCGA-E9-A227-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapytaxotereCR
NADSYN1SNVMissense_Mutationnovelc.1738N>Ap.Asp580Asnp.D580NQ6IA69protein_codingtolerated(0.16)benign(0.007)TCGA-C5-A7X5-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycarboplatinPD
NADSYN1SNVMissense_Mutationnovelc.58N>Cp.Glu20Glnp.E20QQ6IA69protein_codingtolerated(0.12)benign(0.174)TCGA-C5-A902-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
NADSYN1SNVMissense_Mutationc.280N>Tp.Asn94Tyrp.N94YQ6IA69protein_codingdeleterious(0.01)probably_damaging(0.979)TCGA-IR-A3LK-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycisplatinPD
Page: 1 2 3 4 5 6 7 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1